glp-1 parkinson's disease lancet Are diabetes drugs like Ozempic coming for disease? — Parkinson Secrets Exenatide once weekly versus placebo

No randomised controlled trials have demonstrated efficacy in reducing disease activity or joint inflammation, and existing evidence consists only of preclinical studies and theoretical mechanisms

Gastrointestinal Issues Nausea Vomiting Constipation Abdominal discomfort Up to 50% of patients experience GI distress, especially at the start

The extent of weight loss varies by productfor example, semaglutide 2.4mg (Wegovy) has shown average weight loss of approximately 15% after 68 weeks in clinical trials, while liraglutide 3mg (Saxenda) typically achieves 5-8% weight loss

Mechanistically, liraglutide significantly suppressed p38 MAPK/NFB signaling pathways in the sciatic nerves of diabetic rats [11]